efzofitimod   Click here for help

GtoPdb Ligand ID: 13199

Synonyms: ATYR-1923 | ATYR1923 | KRP-R120
Immunopharmacology Ligand
Compound class: Peptide or derivative
Comment: Efzofitimod (ATYR1923) is a Fc fusion protein [1]. The C-terminal 59 amino acids corresponds to the active N-terminal domain of histidyl-tRNA synthetase (HARS), an extracellular non-catalytic isoform that is upregulated by inflammatory cytokine stimulation in the lung. The IgG1 Fc domain extends the peptide's circulating half-life. The HARS domain binds selectively to the cell surface receptor neuropilin 2 (NRP2; O60462, which is an immunomodulatory protein and molecular target for inflammatory diseases [5]. In the airways, NRP2 plays an important role in activation of myeloid cells and their recruitment to inflammatory sites [3]. Efzofitimod was developed as a clinical candidate immunotherpy with potential for immune-mediated fibrotic lung conditions.
No information available.
Summary of Clinical Use Click here for help
Efzofitimod (ATYR1923) is a clinical candidate.
Based on evidence that the efzofitimod target NRP2 was upregulated by inflammatory cytokines in SARS-CoV-2 infections [4], a clinical study was designed to evaluate efzofitimod in patients with severe COVID-19-related pneumonia.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05415137 Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis Phase 3 Interventional aTyr Pharma, Inc.
NCT04412668 Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19 Phase 2 Interventional aTyr Pharma, Inc.
NCT03824392 Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis Phase 1/Phase 2 Interventional aTyr Pharma, Inc. 2